Introduction accurate as it is not possible for dialysis to replace all functions of the kidney. 'Renal support therapy' would be a better terminology to refer to this modality of treatment 1 . The field of RRT has undergone remarkable changes over the last decade and has been evolving rapidly.
Acute kidney injury (AKI), previously termed acute renal failure, refers to a sudden decline in kidney function causing disturbances in fluid, electrolyte, and acid-base balance because of a loss in small solute clearance and decreased glomerular filtration rate (GFR). The nomenclature shift to AKI describes more perfectly the spectrum of disease from subclinical injury to complete organ failure.
Defining AKI in ICU
More than 35 definitions of AKI currently exist in the literature 2 . The Acute Dialysis Quality Initiative convened in 2002 and proposed the RIFLE classification (risk, injury, failure, loss, end-stage kidney disease) specifically for AKI using serum creatinine and urine output in critically ill patients. More recently the Acute Kidney Injury Network (AKIN) has been introduced for staging AKI.
The RIFLE classification 3 was proposed by the Acute Dialysis Quality Initiative specifically for AKI in critically ill patients. The Acute Kidney Injury Network (AKIN) criteria 4 further modified the RIFLE criteria (Table I ). The most current consensus diagnostic criteria for AKI is "an abrupt (within 48 hours) reduction in kidney function, currently defined as an absolute increase in serum creatinine of ≥0.3 mg/dL (≥26.4 μmol/L), a percentage increase in serum creatinine of ≥50% (1.5-fold from baseline), or a reduction in urine output (documented oliguria of <0.5 ml/kg/hr for > 6 hours)." 
Epidemiology of AKI in ICU
AKI in the ICU is common, increasing in incidence 5, 6 and is associated with a substantial increase in morbidity and mortality 7, 8 . AKI occurs in approximately 7% of all hospitalized patients 9 and in up to 36% to 67% of critically ill patients depending on the definition used 10 . Based on 75,000 critically ill adults, more severe AKI occurs in 4% to 25% of all ICU admissions 8, 10 . On average, 5% to 6% of ICU patients with AKI require renal replacement therapy (RRT). Reported mortality in ICU patients with AKI varies considerably between studies depending on AKI definition and the patient population studied (e.g., sepsis, trauma, cardiothoracic surgery, or contrast nephropathy). In the majority of studies, mortality increases proportionately with increasing severity of AKI 11 . In patients with severe AKI requiring RRT, mortality is approximately 50% to 70% 12 . While AKI requiring RRT in the ICU is a well-recognized independent risk factor for in-hospital mortality 13 , even small changes in serum creatinine (S. Cr) are associated with increased mortality. Notably, multiple studies of patients with AKI and sepsis, mechanical ventilation, major trauma, cardiopulmonary bypass, and burn injuries have consistently demonstrated an increased risk of death despite adjustment for co morbidities and severity of illness. Morbidity, a less appreciated consequence of AKI in the ICU, is associated with increased cost, increased length of stay, and increased risk of chronic kidney disease (CKD), including end-stage kidney disease 14 . The true incidence of CKD after AKI is unknown because epidemiologic studies do not routinely or consistently report rates of renal recovery and those that do use variable definitions.
Common causes of AKI in ICU
The most common causes of AKI in the ICU are sepsis, hypovolemia causing renal hypoperfusion, low cardiac output and drugs. Other common causes include hepatorenal syndrome, rhabdomyolysis, urinary flow obstruction, trauma, 
Indications of RRT
Severe AKI results in deregulation in the homeostasis of fluid, potassium, metabolic acids, and waste products. RRT aids to prevent life-threatening complications and to improve homeostasis.
Prevailing criteria 15 for the initiation of RRT in ICU include
• Oliguria (urine output <200 ml/12 h)
• Anuria (urine output: 0-50 ml/12 h)
• Serum creatinine > 400 mmol/L (>4.5 mg/dL)
• Uncompensated metabolic acidosis (pH < 7.1)
• Serum K + > 6.5 mmol/L or rapidly rising values
• Pulmonary edema refractory to diuretics
• Uremic complications (encephalopathy /pericarditis)
• Overdose with a dialyzable toxin
• Hyperthermia and hypothermia
Additional indications for RRT are • Cardiac failure
• Patients requiring a large amount of fluid, parenteral nutrition or blood products, but at risk of developing pulmonary edema or ARDS • Hyperthermia (core temperature >39.5°C) or hypothermia (core temperature <37°C) AKI in the ICU often occurs as a part of MODS, and such patients may have less tolerance of metabolic derangements, such as acidosis and electrolyte imbalances. RRT should be initiated in these patients before the development of extreme metabolic derangements. In patients who require renal support because of metabolic derangements, RRT should not be delayed.
It is preferable to commence RRT at either RIFLE injury stage or at AKIN stage II in critically ill patients when both criteria (urine output and serum creatinine) are included.
Modes of RRT:
The common modes include,
• Intermittent Hemodialysis (IHD)
• Continuous RRT (CRRT)
• Sustained Low Efficiency Dialysis (SLED)
• Peritoneal Dialysis (PD) which can be done by either of the following. 
Intermittent Hemodialysis (IHD)
This technique uses high dialysate flows (500 ml/min). Treatment is applied for short periods of time (3 -4 hours), usually every other day.
IHD has several disadvantages. A reasonably large volume of fluid has to be removed over a short period of time, which can result in hypotension. Repeated hypotensive episodes may delay renal recovery. The use of CRRT is preferred for its improved cardiovascular tolerance over daily intermittent hemodialysis. Solute removal in IHD is episodic. This results in inferior uremic control and acid-base control. Limited fluid and uremic control imposes unnecessary limitations on nutritional support. Rapid solute shifts may increase brain water content and increase in intracranial pressure. Standard low-flux dialyzing membranes trigger the activation of several inflammatory pathways when compared to high-flux synthetic membranes (also used for continuous haemofiltration). This pro-inflammatory effect contributes to further renal damage and delays recovery or even affects mortality.
Continuous RRT (CRRT)
The hemodynamic instability that is often associated with IHD, along with the risk of injury to the recovering kidney, led to the invention of Continuous renal replacement therapy (CRRT) techniques. CRRT is usually initiated with a blood flow of 100 mL/min and gradually increased up to 200 mL/min. CRRT is inherently complex with the requirement for anti-coagulation and the use of high volumes of fluid and is much costlier compared to IHD.
The advantages of CRRT include continuous control of fluid status, hemodynamic stability, control of acid-base status, ability to provide protein-rich nutrition while achieving uremic control, control of electrolyte balance including phosphate and calcium balance, prevention of swings in intracerebral water, minimal risk of infection, and high level of biocompatibility. CRRT has to be considered for patients with cerebral edema, severe hemodynamic instability, persistent on-going metabolic acidosis, and large fluid removal requirements.
Disadvantages of CRRT include higher risk of bleeding due to higher dosage of heparin required, restricted patient mobility. It requires trained personnel and it is expensive.
Sustained Low Efficiency Dialysis (SLED)
Hybrid therapies like SLED and extended daily dialysis have been shown to be safe and effective in critically ill patients 16 . Slow low efficiency diafiltration (SLED-f) by combining SLED with ultrafiltration has been shown to provide stable renal replacement therapy 17 . SLED has better hemodynamic tolerability. It involves no extra machine or device. It combines the effectiveness of CRRT in hemodynamically unstable patients and easy operability of IHD. It involves less heparin dosages and is cost effective. SLED is better for hemodynamically unstable cardiac patients.
Peritoneal Dialysis (PD)
Peritoneal dialysis (PD) was the first modality of renal replacement therapy used for AKI patients 18 . In the 1970s, acute PD was widely accepted for AKI treatment, but its practice declined in favor of hemodialysis 19 . It is frequently used in developing countries because of its lower cost and minimal infrastructural requirements. Recently, interest in using PD to manage AKI patients has been increasing. One important question is whether PD can provide adequate metabolic and fluid control for treating AKI patients.
The work by Gabriel et al 20 showed that, with careful thought and planning, PD could successfully treat critically ill patients. To overcome some of the classic limitations of PD use in AKI, such as a high chance of infection and no metabolic control, they proposed the use of cycles, flexible catheter, and a high volume of dialysis fluid.
In peritoneal dialysis, 1.5 -3 L of peritoneal dialysate solution is infused into the peritoneal cavity and allowed to dwell for a set period of time, usually 2 to 4 hours. A combination of convective clearance and diffusive clearance occurs. The clearance of solutes and water depends on the balance between the movement of solutes and water into the peritoneal cavity versus absorption from the peritoneal cavity into the peritoneal capillary circulation across the peritoneal membrane. The rate of diffusion diminishes with time and eventually stops when equilibration between plasma and dialysate is reached. PD in ICU is indicated when the patient is so hemodynamically unstable that transport to the dialysis unit situated away from the ICU is forbidden. This is especially true when bedside haemodialysis is not available in ICU. PD is found to be more effective in AKI in extremes of age i.e. pediatric patients and elderly patients.
PD is good for hemodynamically unstable patients where IHD or CRRT is difficult. There are no hazards of heparin. Insulin may also be added in patients with diabetes mellitus. A non-absorbable carbohydrate osmotic agent, icodextrin, has been found to be associated with more efficient ultrafiltration than dextrose-containing solutions 21 . PD is also a cheap modality of treatment for AKI in resource poor countries.
Disadvantages of PD include peritonitis, weight gain, hyperglycemia, fluid leaks, protein loss and interference with diaphragm function reducing lung compliance especially when patient is receiving positive pressure breathing by mechanical ventilator.
Current trend in RRT
Results from a large prospective multi-centered observational study of 1200 patients were inconsistent and dependent on the definition of "early" or "late" initiation of RRT 22 . In this study, "late" initiation of RRT was associated with worse out comes (higher crude mortality, longer duration of RRT, increased hospital length of stay, and greater dialysis dependence) when "late" was defined relative to date of ICU admission. A recent meta-analysis nine randomized trials (RCT) comparing intermittent to continuous renal replacement therapy (intermittent RRT vs. CRRT) in AKI demonstrated no difference in mortality or renal recovery defined as independence from RRT 23 . Two studies have shown that CRRT is associated with better long-term kidney recovery when compared to intermittent RRT 24, 25 . In contrast, four RCT that included renal recovery as a primary outcome showed no difference in need for chronic RRT [26] [27] [28] . In the absence of definitive data in support of a particular modality, the choice of RRT modality is currently influenced by multiple factors, including individual site availability, expertise, resources, cost, and likely clinician bias. Hybrid therapies include SLED and extended daily dialysis. These modalities utilize standard intermittent hemodialysis machines but provide a slower solute and fluid removal similar to CRRT technologies. Although there have been no prospective randomized trials evaluating outcomes, hybrid therapies have been shown to be safe and effective alternatives to treating AKI in critically ill patients 29, 30 . The question of optimal modality has not yet been definitively answered. According to several studies in critically ill patients, serum cystatin C is better than S.Cr for early detection of AKI 31, 32 and as a more sensitive marker of small changes in GFR. However in one smaller study there was no correlation between cystatin C and S.Cr 33 . In a recent study, urinary cystatin C but not plasma cystatin C was superior to conventional plasma markers in the early identification of AKI after cardiac surgery 34 .
Future trends
Early identification of AKI with novel candidate biomarkers is an important step in improving outcomes in AKI. These biomarkers help not only in early detection of AKI before the onset of a rise in the serum creatinine, but also aid in the differential diagnosis and prognosis. Serum cystatin C is a sensitive marker of small changes in GFR and has been found to be a useful biomarker for early detection of AKI 35, 36 . In a recent study, urinary cystatin C was found to be superior to conventional plasma markers in the early identification of AKI in post-cardiac surgery patients 37 . Most promising early biomarkers of AKI are neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and interleukin (IL) -18 38 .
Prevention of AKI in critically ill: A novel approach
Those patients prone to develop AKI as evidenced by early biomarkers and with hypotension can use Intra-aortic balloon counter pulsation set just below the renal arteries to ensure perfusion of both the kidneys. This approach is hypothetical and requires study on experimental animals and then on human subjects.
Conclusion
The field of RRT has made remarkable progress over the last decade and is continuing to evolve rapidly. CRRT is now firmly established throughout the world and is perhaps the most commonly used form of RRT. CRRT seems to be superior to IHD with regard to physiological end points. Modifications of IHD, such as SLED, are able to combine the advantages of both IHD and CRRT. PD particularly CAPD is emerging mode of RRT in critically ill. AKI in the ICU most commonly results from multiple insults. Therefore, appropriate and early identification of patients at risk for AKI provides an opportunity to prevent subsequent renal insults and ultimately influence overall ICU morbidity and mortality. Strategies to prevent AKI in these patients are of crucial importance. Critical care nephrology is a fast-emerging subspeciality, and critical care physicians are likely to play a paramount role in the management of patients with renal failure.
